 This clinical trial is conducted in Europe. The purpose of the trial is to investigate the influence on the pharmacokinetics the rate at which the trial drug is eliminated from the body of an oral contraceptive combination drug after multiple administration of semaglutide in female subjects with type 2 diabetes. 